Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2023
This article has no abstract
Epistemonikos ID: 1f25f137c7b3c62475074e6c6cbb6d16854e42b0
First added on: Mar 21, 2025